About KORIO
Korio is a compliance-centric Randomization & Trial Supply Management (RTSM) / Interactive Response Technology (IRT) platform for clinical trials. Founded in 2021, it serves pharmaceutical companies, biotech firms, and research organizations by embedding modern RTSM design intelligence to deliver feature reusability, process repeatability, and GxP-compliant outcomes. Its cloud-based platform manages patient enrollment, randomization, and drug supply logistics across clinical trials.
Company details
Funding
Total raised
$12.3M
Last stage
Series A
Investors
Founders
Ryan Keane
Co-Founder and CEO of Korio, Inc. Previously served as Chief Commercial Officer at Endpoint Clinical. Brings extensive experience in the IRT/RTSM space.
LinkedInChuck Harris
Co-Founder and COO of Korio, Inc. Together with Ryan Keane, brings a combined 30+ years of experience in the IRT space, including scaling a previous IRT startup to a leading global provider.
LinkedInWhat happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.